文献速递乳腺癌支持与姑息治疗

口服伊班膦酸对接受辅助芳香化酶抑制剂的骨量减少乳腺癌患者骨密度影响的2期安慰剂对照单盲试验:单中心BONADIUV试验5年结果

Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
PubMed 文献 · Eur J Cancer · 2019-01-14

BONADIUV试验是一项单盲、随机、安慰剂对照2期研究,2011至2014年入组171例骨量减少的乳腺癌患者,按1:1随机接受口服伊班膦酸150 mg每月一次或安慰剂治疗2年。2年时伊班膦酸组全髋和腰椎T评分变化均显著优于安慰剂组;中位随访63.3个月时,两组总生存率和浸润性疾病无生存率无显著差异。

要点

  • 2年时伊班膦酸组全髋(P=0.0002)和腰椎(P<0.0001)骨密度变化显著优于安慰剂组。
  • 中位随访63.3个月,安慰剂组总生存率97.5%,伊班膦酸组93.0%(P=0.19)。
  • 两组浸润性疾病无生存率无显著差异(P=0.42),不良事件无显著差异。

核心结论

  • 与安慰剂相比,伊班膦酸改善了接受辅助芳香化酶抑制剂治疗的骨量减少女性的骨密度变化。
  • 5年生存分析显示两组总生存率和浸润性疾病无生存率无差异。

研究设计与样本

  • 单盲、随机、安慰剂对照2期研究(BONADIUV试验),单中心开展。
  • 2011年至2014年入组171例骨量减少的乳腺癌患者,按1:1随机接受口服伊班膦酸150 mg每月一次或安慰剂。
  • 治疗 duration 为2年,每6个月评估;主要终点为2年腰椎和全髋T评分均值差异,作为骨密度变化的度量。
  • 在中位随访5年时进行生存结局的次要分析。
  • 临床试验注册号:NCT02616744。

主要发现

  • 研究人群中位年龄60.2岁(范围44-75)。
  • 数据库截止时,中位随访63.3个月(范围2.7-87.3)。
  • 基线时两组全髋T评分(P=0.61)和腰椎T评分(P=0.96)均无差异。
  • 2年随访时,伊班膦酸组全髋(P=0.0002)和腰椎(P<0.0001)的均值变化均具有统计学显著性,优于安慰剂组。
  • 两组不良事件无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: We present the final results of the BONADIUV trial, a single-blind, randomised, placebo-controlled phase 2 study to evaluate the impact of ibandronate treatment on bone mineral density (BMD) in osteopenic women taking aromatase inhibitors (AI). PATIENTS AND METHODS: Between 2011 and 2014, 171 osteopenic patients were randomised in a 1:1 ratio to receive either placebo or oral monthly ibandronate (150 mg). Treatment duration was 2 years, with 6-month evaluation. Primary end-point was the 2-year lumbar spine (LS) and total hip (TH) T-score mean differences as measure of BMD variation. Secondary analyses of survival outcomes have been performed at a 5-year median follow-up. CLINICALTRIALS. GOV IDENTIFIER: NCT02616744. RESULTS: Median age of study population was 60.2 years (range 44-75). At the database cut-off time, the median follow-up was 63.3 months (range 2.7-87.3). No difference in terms of T-score was shown at baseline between arms both for TH (P = 0.61) and LS (P = 0.96). At 2-year follow up, the mean change was statistically significant in favour of ibandronate arm both at TH (P = 0.0002) and LS (P < 0.0001). No significant difference in terms of adverse events was observed between arms. At a median follow-up of 63.3 months (range 2.7-87.3), the overall survival (OS) rate was 97.5% in the placebo group and 93.0% in the ibandronate arm (P = 0.19). The invasive disease-free survival (iDFS) rates did not differ between groups (P = 0.42). CONCLUSIONS: Ibandronate compared to placebo improved BMD change in osteopenic women treated with adjuvant AI. Five-year survival analyses showed no difference between arms in terms of OS and iDFS rates.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Livi L, Scotti V, Desideri I, et al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer. 2019. PMID: 30648627. doi:10.1016/j.ejca.2018.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。